Polymyxin B Eye Drop Dosing for 30-Pound Child
For a 30-pound (approximately 13.6 kg) child, polymyxin B ophthalmic solution should be dosed as 1 drop in the affected eye(s) 4 times daily for 7-10 days, using the standard commercially available formulation containing 10,000 units/mL polymyxin B combined with 1 mg/mL trimethoprim.
Dosing Rationale
The dosing for polymyxin B ophthalmic solution is not weight-based for topical ocular use. The FDA-approved formulation provides a standardized concentration that is safe and effective across pediatric age groups 1.
Key Dosing Parameters:
- Standard dose: 1 drop in affected eye(s) every 6 hours (4 times daily)
- Duration: 7-10 days for bacterial conjunctivitis 2, 3
- Age consideration: Safety established for children ≥2 months of age 1
- Formulation: Polymyxin B sulfate 10,000 units/mL + trimethoprim 1 mg/mL
Clinical Evidence Supporting This Approach
The polymyxin B-trimethoprim combination demonstrates excellent efficacy for pediatric bacterial conjunctivitis. In a randomized trial of 124 children ages 1-18 years, polymyxin B-trimethoprim achieved 96% clinical cure rates by day 7-10, with no statistically significant difference compared to newer fluoroquinolones 2. A multicenter survey of 472 children showed 95% of infected eyes were cured or improved within 7 days using this regimen 4.
Comparative Effectiveness:
While one study showed moxifloxacin achieved faster symptom resolution at 48 hours (81% vs 44%), by day 7-10 the cure rates were equivalent (95-96%), making polymyxin B-trimethoprim a cost-effective first-line option 2, 3.
Safety Considerations
Polymyxin B ophthalmic solution is well-tolerated in children with minimal adverse effects:
- Systemic absorption is negligible: peak serum levels reach only 1 unit/mL polymyxin B and 0.03 mcg/mL trimethoprim at 20 minutes post-instillation 1
- Transient mild-to-moderate discomfort reported in <10% of cases 4
- Contraindication: Do not use in infants <2 months of age 1
Important Caveats:
- Pregnancy/nursing considerations: While systemic trimethoprim has teratogenic concerns at high oral doses, topical ophthalmic use results in minimal systemic exposure. However, caution is still advised 1
- Avoid polymyxin solutions with vasoconstrictors (e.g., phenylephrine combinations) for conjunctivitis treatment, as these are intended for different indications 5
Administration Technique
To optimize drug delivery and minimize systemic absorption:
- Instill 1 drop into the conjunctival sac
- Apply gentle pressure to the lacrimal sac (punctal occlusion) for 1-2 minutes after instillation
- Avoid touching the dropper tip to any surface to prevent contamination
- Space doses approximately 6 hours apart
When to Consider Alternative Therapy
Consider switching from polymyxin B-trimethoprim if:
- No clinical improvement by 48-72 hours
- Suspected gonococcal or chlamydial infection (requires systemic therapy) 5
- Severe purulent discharge suggesting more aggressive bacterial infection
- Culture results indicate resistance to trimethoprim or polymyxin B
For moderate-to-severe bacterial conjunctivitis with copious purulent discharge, obtain cultures before initiating therapy and consider broader-spectrum coverage 5.
Cost-Effectiveness Note
Polymyxin B-trimethoprim represents significant cost savings compared to fluoroquinolones while maintaining equivalent clinical cure rates 2. This makes it an appropriate first-line empiric choice for uncomplicated bacterial conjunctivitis in children, reserving newer agents for treatment failures or specific clinical scenarios.